drugset

drugset / Trial / NCT02110459

Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment

NCT02110459 ↗

Phase 1 Completed 48 enrolled Polyphor Ltd.

Non-randomizedSingle-groupOpen-labelBasic science

Summary

To investigate the pharmacokinetics (PK) of POL7080 in subjects with renal function impairment after single intravenous (IV) infusion of POL7080

Timeline

Start: 2013-04
Primary completion: 2015-07
Completion: 2015-07

Publications

Dale GE, Halabi A, Petersen-Sylla M, Wach A, Zwingelstein C. Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00490-18. doi: 10.1128/AAC.00490-18. Print 2018 Sep.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Murepavadin	Peptide	2.2 mg/kg	Intravenous

Indications